Company profile: Bright Peak Therapeutics
1.1 - Company Overview
Company description
- Provider of immunotherapies for cancer and autoimmune diseases, enabling tissue- and cell-specific cytokine targeting with enhanced efficacy. Offerings include Bright Peak Immunoconjugates combining optimized cytokines with antibodies; a chemical protein synthesis platform for novel proteins; and candidates such as BPT567 (PD1-IL18), BPT331 (PD1-IL2), and BPT331CAPS (PD1-IL2CAPS).
Products and services
- Chemical Protein Synthesis Platform: A custom-engineered technology enabling chemical synthesis and site-specific conjugation to create novel proteins with optimized pharmacological properties for targeted immunotherapies
- Bright Peak Immunoconjugates: A precision-targeted class of biologics combining optimized cytokines with existing antibodies, delivering tissue- and cell-specific cytokine payloads with potential enhanced efficacy in cancer and autoimmune diseases
- BPT331CAPS (PD1-IL2CAPS): A tumor-restricted immunotherapy coupling an anti-PD-1 antibody with an enhanced IL-2 cytokine, conditionally activated in the tumor microenvironment to target and activate immune cells in tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bright Peak Therapeutics
MBrace Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology solutions, including MBRC-101, an antibody-drug conjugate targeting the EphA5 receptor for solid tumors such as breast and lung cancer; SPARTA, a proprietary platform to identify new cancer targets and accelerate ADC development; and a Phase 1/1b clinical trial of MBRC-101 evaluating safety, tolerability, and preliminary efficacy in advanced metastatic solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MBrace Therapeutics company profile →
Alzamend Neuro
HQ: United States
Website
- Description: Provider of biotech therapies for Alzheimer's disease that develops and commercializes drugs, treatments, and cures. Includes AL001, an ionic cocrystal delivering lithium via lithium/proline/salicylate for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD; and ALZN002, a cell-based therapeutic vaccine using a mutant-peptide sensitized cell to restore the patient's immune system's ability to combat Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alzamend Neuro company profile →
MedImmune
HQ: United States
Website
- Description: Provider of biologics research and development as the global biologics research and development arm of AstraZeneca, developing medicines for unmet medical needs worldwide and pioneering innovative research and exploring novel pathways across key therapeutic areas including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; and neuroscience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedImmune company profile →
OncoSec
HQ: United States
Website
- Description: Provider of oncology gene therapies and delivery technologies using electroporation to create transient cell membrane pores for improved IL-12 uptake. Offers TAVO (tavokinogene telseplasmid) intratumoral IL-12 therapy, Visceral Lesion Applicator for internal tumors, a plasmid DNA delivery platform, clinical trials to advance its technology, and global partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoSec company profile →
Calico Labs
HQ: United States
Website
- Description: Provider of research and development focused on the biology that controls aging and lifespan; a Google-sponsored company researching the challenges of aging and disease to diminish their effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calico Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bright Peak Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bright Peak Therapeutics
2.2 - Growth funds investing in similar companies to Bright Peak Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bright Peak Therapeutics
4.2 - Public trading comparable groups for Bright Peak Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →